Page 3 - Astrazeneca

AstraZeneca Covid drug cocktail gives 83% protection over 6 months: Study

The treatment is given in one go, as two sequential shots in the arm

AstraZeneca set for 'modest' profit from Covid-19 vaccine

The Oxford/AstraZeneca vaccine has until now been sold on a not-for-profit basis

AstraZeneca to book modest profit from coronavirus vaccine

British-Swedish pharmaceutical company AstraZeneca said Friday that it will start to book a modest profit from its coronavirus vaccine as it moves away from the nonprofit model

AstraZeneca Pharma India Q2 net profit declines 55% to Rs 12 crore

The drug firm on Tuesday reported a 54.65 per cent decline in its net profit

Pfizer, Astra shots generate more antibodies than natural infection: Study

People who receive the Pfizer or AstraZeneca COVID-19 vaccine have antibody levels significantly higher than those infected with the SARS-CoV-2 virus, according to a study

AstraZeneca pulls request for Swiss approval of Covid-19 shot

AstraZeneca said Thursday that it is withdrawing its application for approval of its COVID-19 vaccine in Switzerland because the country's medical regulator wanted to restrict its use to people over age 50. Switzerland has cleared the BioNTech-Pfizer, Moderna and Johnson & Johnson vaccines for use. However, national medical regulator Swissmedic hadn't yet granted marketing authorization for the AstraZeneca vaccine. The British-Swedish pharmaceutical company said that, since it started rolling submissions for authorization in Switzerland in October 2020, it has been in close communication with the regulator and has continuously provided the requested study results and other pertinent information and documents. AstraZeneca said it has now decided not to pursue the marketing authorization for its COVID-19 vaccine in Switzerland. This decision is based on Swissmedic's requirement to restrict the indication to people 50 years and above. Swissmedic acknowledged AstraZeneca's decision in

UK to donate 20 mn shots of Astra Covid vaccine to developing countries

Johnson made the announcement as he arrived in Rome for a summit of Group of 20 leaders

Astra's Covid-19 vaccine found safe for pregnancy, fertility in study

The rate of miscarriage was roughly the same between the vaccine and placebo groups

WHO chief, Mandaviya talk Covaxin, resuming Covishield supply to COVAX

WHO chief Tedros Adhanom Ghebreyesus discussed the issue of the emergency use listing of Bharat Biotech's COVID-19 vaccine Covaxin and resumption of supplies of the Serum Institute of India-manufactured AstraZeneca vaccine to the COVAX facility among other topics during a telephonic conversation with Health Minister Mansukh Mandaviya. Had a call with @mansukhmandviya, India's Health Minister, to discuss #India's ongoing #COVID19 vaccination programme; the need for a global pandemic agreement; digital health; & traditional medicine. We welcome India's support to strengthen WHO, incl. via flexible, sustainable financing, Ghebreyesus tweeted on Tuesday. The WHO Director-General said that he also discussed with Mandaviya vaccine equity issues: the resumption of SII/AstraZeneca vaccine supplies to #COVAX; the Covaxin Emergency Use Listing process; and technology and license sharing through C-TAP. COVID-19 Technology Access Pool (C-TAP) was launched in May last year for facilitating ...

AstraZeneca sets up clinical data and insights division in India

Drug firm AstraZeneca on Wednesday said it has launched a clinical data and insights division in India for data-related management of its clinical trials. The Bengaluru-based clinical data and insights (CDI) division is a critical advancement to support a growing global portfolio and build on internal data expertise, the drug firm said in a statement. The CDI division works across therapy areas and portfolios, supporting early and late-stage clinical programmes from Phase 1 to Phase 3, with an integrated end-to-end approach for clinical data, analytics, insights and risk management, it added. Currently, a 30-member team, the division is expected to grow to over 100 members by 2022, the drug firm said. "India has seen a constant uptick in investment in areas such as business services, engineering, digital, IT, R&D and product development from global Fortune-500 companies. AstraZeneca in India is no different since its inception, AstraZeneca India has supported the global ...

A step from Covid-19 pills as Merck & Co seeks FDA approval

An application was submitted with the Food and Drug Administration for molnupiravir to treat mild-to-moderate Covid-19 in adults at risk of developing a severe illness that may require hospitalization

AstraZeneca antibody drug effective at treating mild Covid-19 in trial

The cocktail halved the risk of developing severe illness or death compared with a placebo in participants who had been symptomatic for a week or less and weren't hospitalized, Astra said.

Australia drugs regulator approves India-made AstraZeneca vaccine for Covid

China-made vaccine recognised as well as Australia starts to unwind some of the world's most intense pandemic border restrictions.

AstraZeneca to seek US approval for Covid-19 vaccine later this year

The pharmaceutical company AstraZeneca will file a request for approval of its novel coronavirus vaccine in the US later this year, the company said in a statement

New AstraZeneca tie-up to explore vaccine tech for cancer, heart disease

An Imperial College London start-up has tied up with British-Swedish biopharmaceutical major AstraZeneca to explore the therapeutic uses of its vaccine technology

AstraZeneca Pharma India gets nod to import, market Selumetinib capsules

Drug firm AstraZeneca Pharma India on Sunday said it has received import and market permission from the Indian drug regulator for Selumetinib capsules. The company has received the import and market permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg capsules, AstraZeneca Pharma India said in a regulatory filing. The receipt of this permission paves way for the launch of Selumetinib 10 mg & 25 mg capsules in India, subject to the receipt of related statutory approvals and licenses, it added. Selumetinib 10 mg & 25 mg capsules are indicated for treatment of pediatric patients 3 years of age and older with neurofibromatosis type 1 and who have symptomatic, inoperable plexiform neurofibromas, it added.

Covid-19 vaccine: AstraZeneca to develop Imperial's new RNA technology

Under the deal, VaxEquity, a start-up founded by Imperial vaccinologist Robin Shattock, could receive up to $195 million if certain milestones are met

Not many places left for Covid to evade immunity: UK vaccine creator

There aren't many places left for the COVID-19 virus to mutate and evade immunity as it will only get weaker with time, said the creator of the Oxford-AstraZeneca vaccine

India may allow smaller gap between Covishield doses sold privately: Report

Private hospitals and clinics will give their paying patients the option to receive their second dose of the vaccine 4 weeks after the first, down from between 12 and 16 weeks currently, say sources

Serum Institute to invest $68 mn in UK vaccine-maker Oxford Biomedica

British cell therapy firm makes announcement.